The US Government is set to purchase additional 180 million rapid Covid-19 tests in a bid to ensure the availability of test kits across the country. The move will involve an investment of around $1bn, Reuters reported. This investment is in addition to the $2bn commitment made by the government last month to procure test kits. In the US, the production of Covid-19 tests is expected to touch around 200 million per month by December.
SkyWater Technology and NanoDx have entered into a technology transfer collaboration to produce nanoscale sensors that can enhance and expand rapid testing for several indications, including Covid-19. The partnership will enable NanoDx to scale the product and advance with the plan to seek an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a two-minute, point-of-care Covid-19 test. The NanoDx System is designed to identify and quantify biomarkers from a small fluid specimen in less than two minutes.
Todos Medical and its joint venture (JV) partner NLC Pharma have reported positive data from a clinical study that evaluated 3CL protease biomarker assay TolloTest. The trial assessed the sensitivity of the assay compared with PCR in hospitalised Covid-19 patients, other hospitalised patients and individuals exposed to confirmed Covid-19 subjects. The data indicates 100% sensitivity in identifying fully vaccinated asymptomatic Covid-19 patients, after one to three days of exposure.